Background Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder that
presents with a hypertrophied nondilated left ventricle. In the absence of other known …

Hypertrophic cardiomyopathy (HCM) is a genetic disorder defined by the presence of a
hypertrophied nondilated left ventricle in the absence of other known causes. Anatomic …

Background Hypertrophic cardiomyopathy (HCM) presents with a hypertrophied left ventricle
(LV). It is often associated with LV outflow tract obstruction (LVOTO) and a risk for sudden …

Background—Heart transplant is a treatment option for selected patients with hypertrophic
cardiomyopathy (HCM). However, the prevalence, clinical profile, and outcome of this …

Background—In hypertrophic cardiomyopathy (HCM), heart transplant has been
predominantly confined to patients with systolic dysfunction. An underappreciated HCM …

Background Heart transplantation (HT) is the only option for most patients with end‐stage
heart failure and hypertrophic cardiomyopathy (HCM) who fail medical therapy. Data on the …

Cardiac transplantation is a treatment option for patients with hypertrophic cardiomyopathy
(HC) who developed refractory heart failure and/or intractable arrhythmia. However, the …

We present 3 heart transplant recipients who developed hypertrophic cardiomyopathy years
after transplantation. In all 3 cases, the diagnosis was initially made based on …

Objectives The significance of the progression of systolic and diastolic dysfunctions in
hypertrophic cardiomyopathy (HCM) is still an open issue. We sought to evaluate the clinical …

Background. Hypertrophic cardiomyopathy (HCM) in pediatric solid organ transplant
recipients has been reported in association with use of calcineurin inhibitors. However, data …